Member Info for ak12345

Nice little plug for the company. Let's see if it can change the recent downward trajectory of the SP

Something is definitely brewing

I'm quite sure the shares didn't trade as high as $6?

Surprisingly after hours price action

Loan agreed

Along with some other whoppers this afternoon

Couple of big buys landed. 25k and 15k

What's the current level of debt genedrive have from loans etc?

I first noticed this stock during covid when it hit £3 per share

At one point I had a sell order for 80p or so and just missed out by a penny or two

Very sad state of affairs in recent years. From £3 plus to 0 2 of a penny. Less than a thousandth of its value now. Absolutely shocking to say the least!

Excellent progress being made. A healthy cash balance and zero debt. Also exploring non dilutive funding options moving forward.

A good update for shareholders

MD Anderson Clearance to Initiate Pediatric Enrolment in HG-CT-1 Clinical Trial

Bit of a sell off today, maybe because of US government shutdown and implications on FDA

Can't seem to find confirmation that the subscription was made in March as planned. Unless it'll be made once the pediatric arm of the trial actually begins?

Can someone remind me about their investment for pediatric trials? Are we expecting more funds when we start? Just can't remember exactly what the arrangement was. Thanks in advance

Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody

September 25, 2025 at 8:30 AM EDT

BOSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), today announces it will advance its second asset, a fully human anti-IL-6 receptor (“IL-6R”) monoclonal antibody, TZLS-501. There has been heightened industry activity in the IL-6 pathway space, underscored by Novartis’ recent acquisition of Tourmaline Bio for approximately $1.4 billion. Tiziana will pursue non-dilutive funding strategies for the development of TZLS-501 while continuing to advance intranasal foralumab as its lead program.

TZLS-501 is a fully human anti-IL-6 receptor (“IL-6R”) monoclonal antibody (mAb) targeting both the membrane-bound and soluble forms of IL-6R. This dual mechanism of action not only blocks IL-6R signaling but also reduces circulating IL-6 cytokines, which are recognized drivers of inflammation, lung damage, and chronic fibrosis. Tiziana sees potential to develop TZLS-501 as a monotherapy, or in combination with its lead candidate, foralumab, as well as with other anti-inflammatory and anti-infective agents.

Still early in DC. By the time the audience of investors have heard Vlad and digested what he's got, it'll be late evening here. Wouldn't be surprised if there's some significant buying action when the markets reopen in the morning here

Hemo isn't on AIM btw

LTHs will remember talks of a £1 party in old money, so 40p isn't entirely impossible!

For interest, a hundred bag from the lows of last month would only equate to less than 40p in old money, which wouldn't have seemed entirely inconceivable a while back, especially with a buy out

During covid times? It hundred bagged within the space of a few weeks! Not saying the same is going to happen here, but one can dream